NCT02675946: Study of CGX1321 in Subjects With Advanced Solid Tumors

NCT02675946
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for the expansion phase
Exclusions: Patients with known active central nervous system metastases and/or carcinomatous meningitis; Patients with bone metastases with prior history of pathologic fracture; Patients with prior exposure to a WNT inhibitor (except Roll-over cohort); Patients with prior exposure to PD-1 & PD-L1/2 imhibitors
https://ClinicalTrials.gov/show/NCT02675946

Comments are closed.

Up ↑